Efficacy and Safety of Beta Blockers for Patients with Myocardial Infarction in the Percutaneous Coronary Intervention Era: A Systematic Review and Meta-Analysis

Ahmed Irtaza¹, Muhammad Junaid², Muhammad Saqlain³, Ayesha Akram², Ayesha Khan⁴, Areeba Shams Sarwari⁵, Hussain Ali⁶, Salman Ahsan⁷, Tayyab Ahmed⁸, Tuba Talib⁸, Mohammad Ebad Ur Rehman⁹, Huzaifa Ahmad Cheema¹⁰, Adeel Ahmad¹¹, Wajeeh Ur Rehman¹², Abdul Wahab Arif¹³, Sourbha S. Dani¹⁴

- ^{1.} Department of Medicine, MTI-Khyber Teaching Hospital, Peshawar, Pakistan
- ^{2.} Department of Medicine, Faisalabad Institute of Cardiology, Faisalabad, Pakistan
- ^{3.} Department of Medicine, Khyber Medical College, Peshawar, Pakistan
- ^{4.} Department of Medicine, Dow International Medical College, Karachi, Pakistan
- ^{5.} Department of Medicine, Ziauddin Medical University, Karachi, Pakistan
- ^{6.} Department of Medicine, Naples Comprehensive Health, Naples, Florida, USA
- ^{7.} Department of Medicine, Shifa College of Medicine, Islamabad, Pakistan
- ^{8.} Department of Medicine, FMH College of Medicine and Dentistry, Lahore, Pakistan
- ^{9.} Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan
- ^{10.} Department of Medicine, King Edward Medical University, Lahore, Pakistan
- ^{11.} Department of Internal Medicine, Mass General Brigham-Salem Hospital, Salem, MA, USA
- ^{12.} Department of Internal Medicine, United Health Services Hospital, Johnson City, NY, USA
- ^{13.} Department of Internal Medicine, UW Health University Hospital, Madison, WI, USA

^{14.} Division of Cardiovascular Medicine, Beth Israel Lahey Health, Lahey Hospital and

Medical Center, Burlington, MA, USA

Corresponding Authors:

- 1) Mohammad Ebad Ur Rehman; ebadrehman.rehman@gmail.com
- 2) Huzaifa Ahmad Cheema; huzaifaahmadcheema@gmail.com

Keywords: beta blockers, PCI, myocardial infarction.

It is made available under a CC-BY-NC-ND 4.0 International license .

Background

Beta-blockers are commonly prescribed to patients after MI. However, the evidence is based on studies conducted before the widespread use of PCI for treating MI. We conducted this meta-analysis to evaluate beta-blockers' efficacy post-MI in the modern day and age.

Methods

We conducted our search using and one clinical trial registry to get RCTs and propensitymatched observational studies comparing the use of beta-blockers after MI to control in post-MI patients. The primary outcome of our analysis was the likelihood of all-cause mortality.

Results

Our analysis included 3 RCTs and 12 propensity-matched observational studies with a total study population of 102,794. Our results showed a statistically significant decrease in all-cause mortality in the beta-blocker group compared to the non-beta-blocker group (RR 0.63, 95% CI 0.47-0.83; p= 0.001). However, this decrease was not observed when only RCTs were considered (RR 0.91). Beta-blockers were also found to reduce the risk of MI and heart failure with RR of 0.86 (95% CI 0.75-1.00; p=0.05) and 0.84 (95% CI 0.73-0.97; p=0.02), respectively.

Conclusion

Beta-blockers effectively reduce mortality and decrease the risk of MI and heart failure without a significant increase in adverse effects. Thus, our findings support the contemporary use of beta blockers in post-MI patients. However, more long-term studies need to be done to determine the sustained benefits of beta blockers in the context of evolving cardiac care.

Introduction

Beta-blockers have long been a cornerstone in managing acute myocardial infarction (AMI), primarily due to their established benefits in reducing mortality and morbidity observed in earlier clinical trials conducted before the advent of contemporary reperfusion strategies and secondary preventive therapies (1,2). These initial studies significantly influenced clinical guidelines and highlighted the efficacy of beta-blockers in patients with large infarcts and heart failure (HF) (3,4). However, the landscape of AMI treatment has dramatically evolved with the implementation of reperfusion therapies such as percutaneous coronary intervention (PCI) and the routine use of modern pharmacotherapies, including aspirin, statins, and ACE inhibitors/ARBs, prompting a re-evaluation of the role of beta-blockers today (5,6).

Recent meta-analyses and cohort studies have provided mixed evidence regarding betablockers' efficacy in reducing all-cause mortality and cardiovascular events in contemporary AMI management(4,7). For instance, a systematic review of observational studies suggested a reduction in all-cause mortality with beta-blocker use, but this effect was significantly attenuated when accounting for publication bias and small-study effects(8). Furthermore, a comprehensive meta-analysis of randomized controlled trials (RCTs) stratified by era indicated a pronounced benefit in the pre-reperfusion era, with beta-blockers reducing mortality, recurrent myocardial infarction, and angina. However, these benefits appeared to diminish in the reperfusion era, with some adverse effects, such as increased heart failure and cardiogenic shock, becoming more prominent(9).

The ongoing debate about the necessity and duration of beta-blocker therapy post-AMI in the modern therapeutic landscape highlights the need for updated evidence(10). In contemporary practice, where PCI and modern pharmacotherapy are standard, beta-blockers' role must be clearly defined to optimize patient outcomes without exposing them to unnecessary risks(6,11). The current guidelines still recommend beta-blockers post-AMI, but these recommendations are increasingly questioned as new evidence emerges(2,12).

Moreover, the specific patient characteristics and comorbid conditions that might influence beta-blockers' effectiveness are not fully understood. For instance, beta-blockers might benefit patients with reduced ejection fraction or those with a history of heart failure. In contrast, their benefits in patients with preserved ejection fraction and no heart failure are less clear(4). Studies have shown that while beta-blockers reduce the risk of recurrent myocardial infarction and angina in the short term, they do not significantly impact long-term mortality in patients without heart failure(8,13).

In addition to efficacy concerns, the safety profile of beta-blockers is a topic of active investigation. While beta-blockers are generally well-tolerated, their side effects, such as bradycardia, hypotension, and fatigue, can impact patient adherence and quality of life. These side effects may be particularly problematic in older adults and those with comorbid conditions(14). The balance between the benefits and risks of beta-blocker therapy must be carefully considered, especially given the availability of other effective pharmacological agents.

To address these uncertainties, this meta-analysis evaluates the latest evidence on the postdischarge use of beta-blockers in patients with AMI in the current reperfusion era. By incorporating data from recent large-scale RCTs and propensity score-matched observational studies, we seek to provide a clearer understanding of the efficacy and safety of beta-blockers in this patient population, identify factors that may influence their effectiveness, and offer updated insights for clinical practice and future research.

Methods

This meta-analysis was conducted following guidelines outlined in the Cochrane Handbook for Systematic Reviews of Interventions and described in compliance with the Preferred

It is made available under a CC-BY-NC-ND 4.0 International license .

Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement(15). The protocol was registered with PROSPERO (CRD42024572013).

Data Sources and Searches

A systematic literature search was undertaken on the Cochrane Library, MEDLINE, Embase, and ClinicalTrials.gov, which included studies published from January 2000 to June 2024. MeSH terms and keywords for "Myocardial Infarction" and "Adrenergic Beta-Antagonists" were used.

Eligibility Criteria

The inclusion criteria included: (1) study design: RCTs and propensity-matched observational studies (2) patient population: patients with acute myocardial infarction (3) intervention: beta blockers after discharge; and (4) comparator: placebo/control.

The exclusion criteria consisted of (1) all study designs other than RCTs and observational studies that were propensity-matched, (2) studies conducted on patients not having acute MI, and (3) animal studies.

Study Selection and Data Extraction

The studies identified by our search strategy were imported onto Rayyan (rayyan.ai), where duplicate articles were screened for and removed. Two authors (A.I. and A.S.) thoroughly inspected article titles, abstracts, and full texts of the remaining articles and studies, finalizing

them following the pre-specified eligibility criteria. In the event of any disagreements concerning study selection, a senior investigator (M.R.) was consulted.

Data concerning study characteristics, including authors, study design, the origin of the study, patient population (including age and gender), interventions (including administration of beta-blockers or placebo), and primary and secondary outcomes were obtained. Data extraction was done independently by two authors (A.A. and A.K.) using a characterization table created using Microsoft Excel. A senior author was consulted in case of any disputes (M.R.).

Outcomes

The primary outcome assessed was the risk of all-cause mortality. Secondary outcomes included the risk of cardiac death, MI, revascularization, MACE, heart failure, and stroke.

Risk of Bias

We used the revised Cochrane Risk of Bias Tool for RCTs (RoB 2.0) to evaluate the risk of bias in the RCTs present in our analysis. RoB 2.0 assessed bias based on five domains: (1) bias arising from the randomization process; (2) bias due to deviations from intended interventions; (3) bias due to missing outcome data; (4) bias in the measurement of the outcome; and (5) bias resulting from the selection of the reported result(16). The Newcastle-Ottawa Scale (NOS) was used to assess the quality of the propensity-matched observational studies based on three aspects: the selection of study groups, the comparability of these groups, and the establishment of either the exposure or outcome of interest(17). Two investigators (M.S. and M.J.) assessed the risk of bias for each of the included studies as

either high, low, or with some concerns of bias. Any disagreements regarding the risk of bias assessment were settled by a senior investigator (M.R.).

Data Analysis

Meta-analyses were conducted using Review Manager (RevMan, Version 5.4; The Cochrane Collaboration, Copenhagen, Denmark). Risk ratios (RR) with 95% confidence intervals (CIs) for each study were extracted for all the dichotomous outcomes. The random-effects model with the Mantel-Haenszel method was used for the meta-analyses, and forest plots were constructed to display the results. The Higgins I² statistic was calculated to evaluate statistical heterogeneity. We stratified all our analyses according to the study design (RCTs versus observational cohort studies).

Results

Search Results

The initial search retrieved a total of 6732 articles. After removing duplicates and screening titles and abstracts, 423 articles were eligible for full-text screening. Fifteen articles were included in the final systematic review and meta-analysis. Details of the search process and results are depicted in the PRISMA flowchart (Figure 1).

Study Characteristics

Our meta-analysis included 15 studies: 3 RCTs and 12 propensity-matched observational studies. Five studies were from South Korea (18–22), four from Japan (23), two from China

It is made available under a CC-BY-NC-ND 4.0 International license .

(24,25), one from France(4), one from Sweden(26), one study included data from 7 Arabian Gulf countries namely Saudi Arabia, Kuwait, Bahrain, Qatar, UAE, Oman, and Yemen (27), and one had representative populations from Sweden, Estonia, and New Zealand (28). The years of publication ranged from 2013 to 2024. The total study population was 102794 patients, with 45301 (76 %) male. The median age in both groups, beta blocker and control, was 63.4 years. The characteristics of the included studies are summarized in Table 1.

Risk of Bias in Included Studies

The risk of bias in included studies was assessed using Cochrane ROB 2.0 for RCTs and the Newcastle Ottawa Scale for observational studies. Of the three RCTs, Yndigegn et al. (28) showed a high concern for bias, particularly in the randomization domain. Amano et al. (29) and Watanbi et al. (30) showed some concern involving deviation from the intended intervention and measurement of the outcome domain. The Newcastle Ottawa scale score for observational studies ranged from 7-9, indicating a low risk of bias. The summary of risk of bias assessments is depicted in Supplementary Figure 1 and Supplementary Table 1.

Meta-Analysis of Primary Outcome (All-Cause Mortality)

Fifteen studies were included in the analysis of all-cause mortality with 105,034 patients (67254 beta blockers vs 37780 control). There was a significant difference in all-cause mortality between the two groups, with a reduced risk of all-cause mortality in the beta-blockers group as compared to the control group (RR 0.63, 95% CI 0.47-0.83; p= 0.001; I^2 =96%) (Figure 2). In the RCT subgroup, beta-blockers did not significantly improve mortality (RR 0.91, 95% CI 0.72-1.14; p= 0.39; I^2 =0%), whereas in the observational studies subgroup, mortality was significantly lowered by beta-blocker use (RR 0.58, 95% CI 0.42-0.80; p= 0.001; I^2 =97%; p_{interaction}=0.03).

Meta-analysis of Secondary Outcomes

It is made available under a CC-BY-NC-ND 4.0 International license .

Cardiac Death

Eleven studies were included in the analysis for cardiac death with a total of 24926 patients (14762 beta-blockers vs 10164 control). No statistically significant association was found between beta-blocker use in MI patients and cardiac death (RR=0.56, 95% CI 0.25-1.25; p=0.16; I^2 =95%) (Supplementary Figure 7). There was no difference between the beta-blocker group and the control group in RCTs (RR 1.17, 95% CI 0.78-1.75; p= 0.45; I^2 =0%) and observational studies (RR 0.43, 95% CI 0.16-1.17; p= 0.10; I^2 =96%, p_{interaction}=0.07).

Myocardial Infarction

Eight studies were included in the analysis of myocardial infarction with a total of 81299 patients (54478 beta-blockers vs 26821 control). A statistically significant difference was noted in the risk of myocardial infarction between the two groups, with reduced risk in the beta-blocker group as compared to the control group (RR 0.86, 95% CI 0.75-1.00; p=0.05; I^2 =41%) (Supplementary Figure 3). The results were comparable for RCTs and observational cohort studies (p_{interaction}=0.6).

Major Adverse Cardiac Event (MACE)

Six studies were included in the analysis of MACE with a total of 12069 patients (7421 Beta Blockers vs 4648 Control). The analysis revealed no statistically significant difference in the risk of MACE between the two groups, with a p-value of 0.42. (RR 0.92, 95% CI 0.75-1.12; p=0.42; $I^2=65\%$) (Supplementary Figure 4). There was no difference between the results of RCTs and cohort studies ($p_{interaction}=0.78$).

Stroke

Eight studies were included in the stroke analysis with a total of 80,040 patients (54197 Beta Blockers vs 25843 Control). The two regimens were comparable (RR 0.69, 95% CI 0.40-

1.17; p=0.17; I^2 =93%) (Supplementary Figure 5). The results were similar between RCTs and observational studies (p_{interaction}=0.22).

Heart Failure

Seven studies in our meta-analysis reported results for heart failure. The risk of heart failure in the beta-blocker group is lower than in the control group (RR=0.84, 95% CI 0.73-0.97; p=0.02; $I^2=0\%$) (Supplementary Figure 6). There was no difference in the results between RCTs and cohort studies ($p_{interaction}=0.18$).

Revascularization

Six studies of our meta-analysis were included in the analysis for revascularization. No statistically significant association was found between beta-blocker use in MI patients and the need for revascularization (RR=0.97, 95% CI 0.90-1.04; p=0.43; $I^2=17\%$) (Supplementary Figure 7). The results were comparable for RCTs and observational studies ($p_{interaction}=0.57$).

Discussion

In this meta-analysis, including RCTs and propensity score-matched observational studies, we evaluated beta-blockers' efficacy after discharge in patients with myocardial infarction. The use of beta-blockers after discharge was noted to be associated with a reduction in all-cause mortality, myocardial infarction, and heart failure. There were no significant differences in cardiac death, MACE, stroke, or revascularization. However, in the stratified analysis of RCTs, beta-blockers did not significantly improve all-cause mortality.

The lack of benefit in terms of mortality based on RCTs in the contemporary era significantly dampens beta-blockers' role in this population, contrasting with pre-PCI recommendations. Given the variability in effect size, it is essential to consider individual patient factors when

prescribing beta blockers. Personalized treatment approaches could help optimize outcomes and minimize potential adverse effects. Based upon the data available in observational studies included in our study, our findings can advocate for the continued use of beta-blockers as a standard therapeutic option in post-MI care, particularly to reduce all-cause mortality or in those at higher risk of recurrent events. However, further RCTs are required to provide results with a better strength of evidence.

A previous meta-analysis by Hu M. et al. also reported a reduced risk of all-cause mortality with beta-blocker use in patients with MI (31). However, it also showed significant results in cardiac death, myocardial infarction, and revascularization without influence on heart failure, MACE, or stroke. A meta-analysis conducted by Maqsood et al. (32) and Dahl Aarvik et al. (33) also favored the use of beta blockers in causing a reduction in all-cause mortality. However, these meta-analyses also only included data from observational studies, with Hu M. et al. having only one RCT. Our meta-analysis included 3 RCTs and propensity scorematched observational studies, thus limiting the impact of confounders on our results. Including more RCTs and observational studies with propensity score matching in our study showed differences in secondary outcomes from previous meta-analyses.

Beta-blockers have long been a cornerstone in managing patients following an MI. Our study aimed to evaluate the efficacy and safety of beta blockers in contemporary post-MI patients, considering the advances in medical therapy and revascularization techniques. The use of beta blockers in patients with acute myocardial infarction was first evidenced long before the reperfusion era when the First International Study of Infarct Trial (ISIS-1) in 1986 showed a significant reduction in vascular death with the use of beta blockers compared to non-use of beta-blockers (3.87% vs 4.57%, P-value < 0.05) (34). However, later in 2005, clopidogrel and metoprolol in the Myocardial Infarction Trial (COMMIT) showed no significant differences

in all-cause death, myocardial infarction, or cardiac arrest with the use of metoprolol compared to no use of beta-blocker (P=0.01) (35). These differences in results can be attributed to the advancement in treatments in the reperfusion era. In the ISIS-1 trial, only 5% of patients received antiplatelets, whereas, in COMMIT, all patients received aspirin, with 50% receiving dual antiplatelet therapy and 54% receiving fibrinolytic agents. Advances in PCI techniques and the increased use of aspirin, clopidogrel, and statins have substantially decreased all-cause mortality. Consequently, it is hypothesized that modern treatment modalities have reduced the effectiveness of beta blockers due to advancements in the reperfusion era (36).

The potential impact of beta-blockers on patients with acute myocardial infarction (AMI) can be attributed to several mechanisms. AMI significantly increases monocyte accumulation in atherosclerotic plaques, leading to larger and more complex lesions. Additionally, the sympathetic nervous system activation activates neuroimmune connections in the bone marrow, boosting extramedullary myelopoiesis. Prior beta-blocker therapy was associated with decreased circulating monocytes after myocardial infarction, attenuating atherosclerosis and improving long-term patient outcomes (37). Adverse cardiac remodeling in the form of ventricular dilation following AMI is linked to a worse prognosis (38), and beta-blockers have been shown to improve this left ventricular remodeling process (39). Beta-blockers are class II antiarrhythmic drugs known to reduce the occurrence of both short- and long-term ventricular arrhythmias, which are major causes of 90-day mortality (40–42). Much of the benefit of beta blockers owes to the neurohormonal blockage of sympathetic drive. This results in reduced heart rate, myocardial oxygen demand, and decreased levels of circulating vasoconstrictors, leading to reduced peripheral resistance and myocardial work. All these

effects are cardioprotective, helping reduce cardiomyocyte death and prevent deleterious cardiac remodeling.

A notable strength of this analysis is the inclusion of more RCTs and propensity scorematched observational studies, which enhances the generalizability of our findings to current clinical practice. Furthermore, the risk of bias assessment, detailed in Supplementary Table 1, highlights that most included studies demonstrated strong methodological quality. For instance, studies such as Choo (2013), Ishak (2023), and Konishi (2015) each scored 9 out of 9, indicating robust study designs. We also conducted an extensive literature review across multiple databases, capturing a broad spectrum of studies, stringent inclusion criteria, and robust quality assessment methods to minimize bias.

A few important limitations linked with this meta-analysis also need to be addressed. The high heterogeneity (I² = 96%) highlights the need to interpret the pooled results carefully. Factors such as differences in study design, patient demographics, and treatment protocols contribute to this variability. Additionally, the observational nature of most included studies limits our ability to infer causality. The differences in results observed between observational studies and RCTs on stratified analysis may be because our RCT-based analysis was underpowered compared to observational studies. This also brings forth the need to conduct more RCTs to develop a more accurate picture of the role of beta blockers in post-MI patients. Moreover, the RCT by Yndigegn 2024 showed a high risk of bias assessment attributed to the selection process, which might be due to an inadequate randomization process. Future RCTs are necessary to confirm these findings and address the heterogeneity observed.

It is made available under a CC-BY-NC-ND 4.0 International license .

Conclusions

While our meta-analysis underscores the significant mortality benefit of beta blockers in contemporary post-MI patients in the combined analysis, it fails to confidently support the continued use of beta blockers as a crucial component of post-MI management on stratified analysis due to differential results between observational studies and RCTs. Tailoring treatment to individual patient profiles will be key to maximizing clinical benefits and improving patient outcomes

Statements and Declarations

Financial support

No financial support was received for this study.

Conflicts of interest

The authors report no relationships that could be construed as a conflict of interest.

Acknowledgments

Not applicable.

Availability of data

The data supporting this study's findings are available from the corresponding author upon

reasonable request.

References

 Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139–228.

- Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016 Jan 14;37(3):267–315.
- The current status of beta blockers' use in the management of hypertension PMC [Internet]. [cited 2024 Jul 5]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362137/
- 4. Puymirat E, Riant E, Aissaoui N, Soria A, Ducrocq G, Coste P, et al. β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. BMJ. 2016 Sep 20;354:i4801.
- Misumida N, Harjai K, Kernis S, Kanei Y. Does Oral Beta-Blocker Therapy Improve Long-Term Survival in ST-Segment Elevation Myocardial Infarction With Preserved Systolic Function? A Meta-Analysis. J Cardiovasc Pharmacol Ther. 2016 May;21(3):280–5.
- Nakatani D, Sakata Y, Suna S, Usami M, Matsumoto S, Shimizu M, et al. Impact of beta blockade therapy on long-term mortality after ST-segment elevation acute myocardial infarction in the percutaneous coronary intervention era. Am J Cardiol. 2013 Feb 15;111(4):457–64.
- Lee PH, Park GM, Kim YH, Yun SC, Chang M, Roh JH, et al. Effect of Beta Blockers and Renin-Angiotensin System Inhibitors on Survival in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Medicine (Baltimore). 2016 Mar;95(10):e2971.
- Bangalore S, Bhatt DL, Steg PG, Weber MA, Boden WE, Hamm CW, et al. β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circ Cardiovasc Qual Outcomes. 2014 Nov;7(6):872–81.
- 9. Hioki H, Motoki H, Izawa A, Kashima Y, Miura T, Ebisawa S, et al. Impact of oral betablocker therapy on mortality after primary percutaneous coronary intervention for Killip class 1 myocardial infarction. Heart Vessels. 2016 May;31(5):687–93.
- 10. Kernis SJ, Harjai KJ, Stone GW, Grines LL, Boura JA, O'Neill WW, et al. Does betablocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? J Am Coll Cardiol. 2004 May 19;43(10):1773–9.
- 11. Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebocontrolled trial. Lancet Lond Engl. 2005 Nov 5;366(9497):1622–32.
- 12. Lee PH, Park GM, Kim YH, Yun SC, Chang M, Roh JH, et al. Effect of Beta Blockers and Renin-Angiotensin System Inhibitors on Survival in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Medicine (Baltimore). 2016 Mar;95(10):e2971.

- Lee YH, Park JS, Tahk SJ, Hwang GS, Yoon MH, Choi SY, et al. β-Blocker Therapy in the Era of Primary Percutaneous Intervention for ST Elevation Myocardial Infarction. Cardiology. 2015;132(2):91–100.
- Yamada K, Tsuji H, Tokunaga S, Kurimoto K, Maeba H, Matsuhisa S, et al. Effect of beta-blockers on the mortality of Japanese patients with myocardial infarction. Int J Cardiol. 2006 Apr 14;108(3):309–13.
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71.
- 16. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019 Aug 28;366:14898.
- 17. Ottawa Hospital Research Institute [Internet]. [cited 2024 Jul 5]. Available from: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
- Choo EH, Chang K, Ahn Y, Jeon DS, Lee JM, Kim DB, et al. Benefit of β-blocker treatment for patients with acute myocardial infarction and preserved systolic function after percutaneous coronary intervention. Heart. 2014;100(6):492–9.
- 19. Joo SJ, Kim SY, Lee JG, Beom JW, Choi JH, Park HK, et al. Association of the medical therapy with beta-blockers or inhibitors of renin-angiotensin system with clinical outcomes in patients with mildly reduced left ventricular ejection fraction after acute myocardial infarction. Medicine (Baltimore). 2022;101(42):e30846.
- 20. Lee PH, Park GM, Han S, Kim YG, Lee JY, Roh JH, et al. Beta-blockers provide a differential survival benefit in patients with coronary artery disease undergoing contemporary post-percutaneous coronary intervention management. Sci Rep. 2020;10(1):22121.
- Won H, Suh Y, Kim GS, Ko YG, Hong MK. Clinical impact of beta blockers in patients with myocardial infarction from the Korean National Health Insurance Database. Korean Circ J. 2020;50(6):499–508.
- 22. Yang JH, Hahn JY, Song YB, Choi SH, Choi JH, Lee SH, et al. Association of betablocker therapy at discharge with clinical outcomes in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. JACC Cardiovasc Interv. 2014;7(6):592–601.
- 23. Yang JH, Hahn JY, Song YB, Choi SH, Choi JH, Lee SH, et al. Association of Beta-Blocker Therapy at Discharge With Clinical Outcomes in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2014 Jun 1;7(6):592–601.
- 24. Chen RZ, Liu C, Zhou P, Li JN, Zhou JY, Wang Y, et al. Prognostic impacts of βblockers in acute coronary syndrome patients without heart failure treated by percutaneous coronary intervention. Pharmacol Res. 2021;169:105614.
- 25. Wen X song, Luo R, Liu J, Duan Q, Qin S, Xiao J, et al. Short-term/long-term prognosis with or without beta-blockers in patients without heart failure and with preserved ejection

fraction after acute myocardial infarction: a multicenter retrospective cohort study. BMC Cardiovasc Disord. 2022;22(1):193.

- 26. Ishak D, Aktaa S, Lindhagen L, Alfredsson J, Dondo TB, Held C, et al. Association of beta-blockers beyond 1 year after myocardial infarction and cardiovascular outcomes. Heart. 2023 Aug 1;109(15):1159.
- 27. Al-Bawardy R, Alqarawi W, Al Suwaidi J, Almahmeed W, Zubaid M, Amin H, et al. The Effect of Beta-Blocker Post-Myocardial Infarction With Ejection Fraction> 40% Pooled Analysis From Seven Arabian Gulf Acute Coronary Syndrome Registries. Angiology. 2024;00033197241227025.
- Yndigegn T, Lindahl B, Mars K, Alfredsson J, Benatar J, Brandin L, et al. Beta-blockers after myocardial infarction and preserved ejection fraction. N Engl J Med. 2024;390(15):1372–81.
- 29. Amano M, Izumi C, Watanabe H, Ozasa N, Morimoto T, Bingyuan B, et al. Effects of long-term carvedilol therapy in patients with ST-segment elevation myocardial infarction and mildly reduced left ventricular ejection fraction. Am J Cardiol. 2023;199:50–8.
- 30. Watanabe H, Ozasa N, Morimoto T, Shiomi H, Bingyuan B, Suwa S, et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PLoS One. 2018;13(8):e0199347.
- Hu M, Hu S, Gao X, Yang Y. Beta-Blocker Use after Discharge in Patients with Acute Myocardial Infarction in the Contemporary Reperfusion Era. Medicina (Mex). 2022;58(9).
- 32. Maqsood MH, Alam M, Atar D, Birnbaum Y. Efficacy of Long-Term Oral Beta-Blocker Therapy in Patients Who Underwent Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction With Preserved Left Ventricular Ejection Fraction: A Systematic Review and Meta-analysis. J Cardiovasc Pharmacol. 2021 Jan 1;77(1):87–93.
- 33. Dahl Aarvik M, Sandven I, Dondo TB, Gale CP, Ruddox V, Munkhaugen J, et al. Effect of oral β-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis. Eur Heart J - Cardiovasc Pharmacother. 2019 Jan 1;5(1):12–20.
- Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet Lond Engl. 1986 Jul 12;2(8498):57–66.
- 35. Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebocontrolled trial. Lancet Lond Engl. 2005 Nov 5;366(9497):1622–32.
- 36. Exner DV, Reiffel JA, Epstein AE, Ledingham R, Reiter MJ, Yao Q, et al. Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: the antiarrhythmics versus implantable defibrillators (AVID) trial. J Am Coll Cardiol. 1999 Aug 1;34(2):325–33.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 37. Dutta P, Courties G, Wei Y, Leuschner F, Gorbatov R, Robbins CS, et al. Myocardial infarction accelerates atherosclerosis. Nature. 2012 Jul 1;487(7407):325–9.
- Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990 Apr 1;81(4):1161–72.
- Doughty RN, Whalley GA, Walsh HA, Gamble GD, López-Sendón J, Sharpe N. Effects of Carvedilol on Left Ventricular Remodeling After Acute Myocardial Infarction. Circulation. 2004 Jan 20;109(2):201–6.
- O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary. Circulation. 2013 Jan 29;127(4):529–55.
- 41. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981 Apr 2;304(14):801–7.
- 42. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA. 1982 Mar 26;247(12):1707–14.

It is made available under a CC-BY-NC-ND 4.0 International license .

Figure Legend:



Figure 1: PRISMA Flowchart

It is made available under a CC-BY-NC-ND 4.0 International license .

	Rota Blo	ckore	Cont	rol		Riek Patio	Rick Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M.H. Random, 95% CL	M-H. Bandom, 95% Cl
1.1.1 Cohort	Lvoitto	Total	Liono	rotai	Troigin	in the tail and the tail of tail o	
Al-Bawardy 2024	10	282	25	294	53%	0.42 (0.20, 0.85)	- _
Chen 2021	14	328	15	328	5.4%	0.93 [0.46, 1.90]	
Chon 2013	33	2424	262	595	7.2%		
Ishak 2023	2872	34253	945	9365	8.0%	0.83 [0.77, 0.89]	•
Joo 2021	174	3240	116	1775	7.6%	0.82 [0.65, 1.03]	
Konishi 2015	14	103	24	103	5.9%	0.58 [0.32, 1.06]	
Lee 2020	770	7333	902	7333	8.0%	0.85 [0.78, 0.93]	*
Nakatani 2013	108	1923	120	1923	7.6%	0.90 [0.70, 1.16]	
Puymirat 2016	24	383	28	383	6.3%	0.86 [0.51, 1.45]	_ _
Wen 2022	9	415	7	420	4.1%	1.30 [0.49, 3.46]	-
Won 2020	345	10624	525	10624	7.9%	0.66 [0.58, 0.75]	+
Yang 2014	74	2650	54	1325	7.2%	0.69 [0.49, 0.97]	
Subtotal (95% CI)		63958		34468	80.5%	0.58 [0.42, 0.80]	•
Total events	4447		3023				
Heterogeneity: Tau ² =	0.29; Chi ^a	^e = 350.6	2, df = 11	(P < 0.0	0001); P	= 97%	
Test for overall effect:	Z = 3.26 (I	P = 0.001)				
1.1.2 RCT							
Amano 2023	19	394	24	400	6.0%	0.80 [0.45, 1.44]	
Watanabi 2018	20	394	24	400	6.0%	0.85 [0.48, 1.51]	
Yndigegn 2024	97	2508	103	2512	7.5%	0.94 [0.72, 1.24]	-
Subtotal (95% CI)		3296		3312	19.5%	0.91 [0.72, 1.14]	•
Total events	136		151				
Heterogeneity: Tau ² =	0.00; Chi ^a	² = 0.30, (df = 2 (P =	= 0.86); I	²=0%		
Test for overall effect:	Z = 0.86 (I	P = 0.39)					
Total (95% CI)		67254		37780	100.0 %	0.63 [0.47, 0.83]	•
Total events	4583		3174				
Heterogeneity: Tau ² =	0.26; Chi ^a	²= 352.7	7, df = 14	(P ≤ 0.0	0001); l²:	= 96%	
Test for overall effect:	Z = 3.22 (I	P = 0.001)				Favours Beta Blockers Favours Control
Test for subgroup diff	erences: (Chi ² = 4.8	3, df = 1	(P = 0.03)	3), I ² = 79,	3%	

Figure 2: Forest Plot of All-Cause Mortality

It is made available under a CC-BY-NC-ND 4.0 International license .

								Smoki	STE		
				Mean Age,	Male	HTN		ng	MI	PCI	
Study	Study		Sample	in years	(%)	(%)	Diabete	(%)	(%)	(%)	LVEF
ID	Design	Country	Size*	(SD)**	***	***	s (%)	***	***	***	(%)
		Saudi									
		Arabia,									
		Kuwait,									
		Bahrain,									
Al-		Qatar,									
Bawar		UAE,	954	54.8 (12.8)							
dy	Observatio	Oman, and	(477 vs	vs 54.5						13.	
2024	nal	Yemen	477)	(12.5)	87.5	33.9	36.6	31.4	100	9	>40
Amano											
2023	RCT	Japan	794	64.3	80.5	60	24	47.2	100	100	NR
			656								
Chen	Observatio		(328 vs							10.	
2021	nal	China	328)	59.4 (11.8)	82.8	54.1	26.8	NR	92.1	2	57.8(4.1)
			1182	62.9 (11.4)							
Choo	Observatio	South	(591 vs	vs 63.0							
2013	nal	Korea	591)	(12.8)	69.5	48.9	41	39.4	57.4	NR	<50
			43618	64 (56–71)							
Ishak	Observatio		(34253	vs 65 (57–						3.2	
2023	nal	Sweden	vs	74) ***	NR	38.24	13	30	36.2	7	>50

It is made available under a CC-BY-NC-ND 4.0 International license .

			9365)								
			5,015								
			(3240	65.3 (12.2)							
Joo	Observatio	South	vs	vs 65.5							
2021	nal	Korea	1775)	(12.8)	73.5	47.2	26	38.2	40.7	NR	>50
			206	64.3 (11.8)							
Konish	Observatio		(103 vs	vs 64.9							
i 2015	nal	Japan	103)	(10.6)	80.6	61.6	41.3	35.9	100	100	>40
			14666								
			(7333	65 (55–75)							
Lee	Observatio	South	vs	vs 65 (55–							
2020	nal	Korea	7333)	75) ***	75.2	98.4	57.3	NR	NR	94	NR
			3846								
			(1923								
Nakata	Observatio		vs	64.4 (11.4)							
ni 2013	nal	Japan	1923)	vs 65.1 (12)	77.1	60	32.7	65.6	100	78	NR
			766	66.9 (13.7)							
Puymir	Observatio		(383 vs	vs 65.9						56.	
at 2016	nal	France	383)	(13.5)	69.5	55.22	28.9	32.5	47.9	3	>50
Watan			794	63.9 (11.2)							
abe			(394 vs	vs 64.5							
2018	RCT	Japan	400)	(11.3)	80.5	59.6	22.5	47.1	100	100	≥40
Wen	Observatio		848	63 (55-72)						72.	
2022	nal	China	(424 vs	vs 64 (54-	79.7	52.2	29.6	67	61	7	>50

It is made available under a CC-BY-NC-ND 4.0 International license .

			424)	72) ***							
			21248								
			(10624	62 (52–71)							
Won	Observatio	South	vs	vs 61 (52–							
2020	nal	Korea	10624)	71) ***	75.2	47.3	28.1	NR	NR	NR	NR
			3975								
			(2650	66 (55-74)							
Yang	Observatio	South	vs	vs 65 (55-							
2014	nal	Korea	1325)	74) ***	73.03	43.6	25.3	45.7	100	100	50
		Sweden,	5020								
Yndige		Estonia,	(2508								
gn		New	vs	65 (57-73)						94.	
2024	RCT	Zealand	2512)	***	77.5	46.2	13.9	20.1	35.2	9	>50

Table 1: Characteristics of Included Studies

*Total Sample Size (Sample Size of Beta Blocker Group Versus Sample Size of Control Group)

** Mean Age of Beta Blocker Group Versus Mean Age of Control Group

*** Median Age in years (IQR)

SD: Standard Deviation, HTN: Hypertension, STEMI: ST Elevation Myocardial Infarction, PCI:

Percutaneous Coronary Intervention, LVEF: Left Ventricular Ejection Fraction, UA: United Arab

Emirates, RCT: Randomized Controlled Trial

It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary Data:







	Beta Blo	ckers	Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
1.2.1 Cohort							
Chen 2021	6	328	7	328	8.5%	0.86 [0.29, 2.52]	
Choo 2013	18	2424	184	595	9.8%	0.02 [0.01, 0.04]	- - -
Joo 2021	112	3240	84	1775	10.0%	0.73 [0.55, 0.96]	
Konishi 2015	6	103	18	103	9.0%	0.33 [0.14, 0.81]	_
Nakatani 2013	27	1923	34	1923	9.7%	0.79 [0.48, 1.31]	
Puymirat 2016	10	383	21	383	9.3%	0.48 [0.23, 1.00]	_
Wen 2022	5	415	3	420	7.6%	1.69 [0.41, 7.01]	
Yang 2014	40	2650	37	1325	9.8%	0.54 [0.35, 0.84]	
Subtotal (95% CI)		11466		6852	73.7%	0.43 [0.16, 1.17]	
Total events	224		388				
Heterogeneity: Tau ² =	1.90; Chi ²	= 177.3	2, df = 7 (ł	□ < 0.00	001); I² =	96%	
Test for overall effect:	Z = 1.65 (F	° = 0.10)					
4.0.0.007							
1.2.2 RC1			_				
Amano 2023	6	394	5	400	8.3%	1.22 [0.37, 3.96]	
Watanabi 2018	6	394	5	400	8.3%	1.22 [0.37, 3.96]	
Yndigegn 2024	38	2508	33	2512	9.8%	1.15 [0.73, 1.83]	<u> </u>
Subtotal (95% CI)		3296		3312	26.3%	1.17 [0.78, 1.75]	+
Total events	50		43				
Heterogeneity: Tau ² =	0.00; Chi ²	= 0.01, (df = 2 (P =	0.99); I	²=0%		
Test for overall effect:	Z = 0.75 (F	P = 0.45)					
Total (95% CI)		14762		10164	100.0%	0.56 [0.25, 1.25]	
Total events	274		431				-
Heterogeneity: Tau ² =	1.63: Chi ²	= 199 በ	5. df = 10	(P < 0 N	0001): I ^z a	= 95%	
Test for overall effect:	Z = 1.41 (F	P = 0.16	-, 70				0.01 0.1 1 10 100
Test for subaroup diff	erences: C	;hi² = 3.2	7. df = 1 (P = 0.07	n. I ² = 69.	4%	Favours Beta Blockers Favours Control

It is made available under a CC-BY-NC-ND 4.0 International license .

	Beta Blo	ckers	Cont	rol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
1.4.1 Cohort							
Ishak 2023	2598	34253	787	9365	36.7%	0.90 [0.84, 0.97]	•
Joo 2021	70	3240	33	1775	9.5%	1.16 [0.77, 1.75]	
Wen 2022	1	415	12	420	0.5%	0.08 [0.01, 0.65]	
Won 2020	212	10624	286	10624	25.4%	0.74 [0.62, 0.88]	-
Yang 2014	30	2650	19	1325	5.5%	0.79 [0.45, 1.40]	
Subtotal (95% CI)		51182		23509	77.6%	0.85 [0.69, 1.04]	•
Total events	2911		1137				
Heterogeneity: Tau ² =	0.03; Chi ^a	² =11.12	, df = 4 (P	= 0.03);	I ^z = 64%		
Test for overall effect:	Z = 1.55 (F	^o = 0.12)					
1.4.2 RCT							
Amano 2023	7	394	10	400	2.1%	0.71 [0.27, 1.85]	
Watanabi 2018	7	394	10	400	2.1%	0.71 [0.27, 1.85]	
Yndigegn 2024	112	2508	117	2512	18.1%	0.96 [0.74, 1.23]	+
Subtotal (95% CI)		3296		3312	22.4%	0.92 [0.73, 1.17]	♦
Total events	126		137				
Heterogeneity: Tau ² =	0.00; Chi ^a	² = 0.66, i	df = 2 (P =	= 0.72); ř	²=0%		
Test for overall effect:	Z = 0.65 (I	- = 0.51)					
Total (95% CI)		54478		26821	100.0%	0.86 [0.75, 1.00]	•
Total events	3037		1274				
Heterogeneity: Tau ² =	0.01; Chi ^a	²= 11.94	, df = 7 (P	= 0.10);	I ² = 41%		
Test for overall effect:	Z = 2.00 (^o = 0.05)					Eavoure bota blockore Eavoure control
Test for subaroup diff	erences: (2hi² = 0.2	28. df = 1	(P = 0.60)), ² = 0%)	Favous beta blockers Favous collion

Supplemental Figure 3: Forest Plot of Myocardial Infarction

Supplemental Figure 4: Forest Plot of Major Adverse Cardiovascular Events

	Beta Bloc	kers:	Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
1.3.1 Cohort							
Chen 2021	51	328	29	328	12.8%	1.76 [1.14, 2.70]	
Joo 2021	343	3240	223	1775	25.9%	0.84 [0.72, 0.99]	
Wen 2022	11	415	19	420	6.1%	0.59 [0.28, 1.22]	
Yang 2014	219	2650	140	1325	23.5%	0.78 [0.64, 0.96]	
Subtotal (95% CI)		6633		3848	68.3%	0.92 [0.68, 1.25]	•
Total events	624		411				
Heterogeneity: Tau ² =	0.06; Chi ^z	= 12.64	df = 3 (P	= 0.00	5); I ² = 76	:%	
Test for overall effect:	Z = 0.53 (P	= 0.60)					
1.3.2 RCT							
Amano 2023	18	394	23	400	8.2%	0.79 [0.44, 1.45]	
Watanabi 2018	127	394	130	400	23.6%	0.99 [0.81, 1.21]	+
Subtotal (95% CI)		788		800	31.7%	0.97 [0.80, 1.17]	•
Total events	145		153				
Heterogeneity: Tau ² =	: 0.00; Chi ^z	= 0.48, (df=1 (P∶	= 0.49);	I ² = 0%		
Test for overall effect:	Z = 0.31 (P	= 0.75)					
Total (95% CI)		7421		4648	100.0%	0.92 [0.75, 1.12]	•
Total events	769		564				
Heterogeneity: Tau ² =	: 0.03; Chi ^z	= 14.22	df = 5 (P	= 0.01); l² = 659	6	
Test for overall effect:	Z = 0.81 (P	= 0.42)					Eavours beta blockers Eavours control
Test for subgroup diff	ferences: C	hi² = 0.0	8, df = 1	(P = 0.7)	⁷ 8), l ² = 0 ⁴	%	

It is made available under a CC-BY-NC-ND 4.0 International license .

	Beta Blo	ckers	Cont	rol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
1.2.1 Cohort							
Al-Bawardy 2024	5	477	4	477	8.4%	1.25 [0.34, 4.63]	
Choo 2013	9	2424	61	595	13.2%	0.04 [0.02, 0.07]	- - -
Ishak 2023	1136	34253	318	9365	16.9%	0.98 [0.86, 1.10]	•
Joo 2021	45	3240	16	1775	14.3%	1.54 [0.87, 2.72]	+
Puymirat 2016	0	277	1	95	2.4%	0.12 [0.00, 2.80]	
Won 2020	176	10624	159	10624	16.6%	1.11 [0.89, 1.37]	. +
Subtotal (95% CI)		51295		22931	71.9%	0.57 [0.28, 1.13]	◆
Total events	1371		559				
Heterogeneity: Tau ² =	0.54; Chi ^a	= 92.98	df = 5 (P	< 0.000	01); I ^z = 9	5%	
Test for overall effect:	Z = 1.62 (F	^o = 0.11)					
1.2.2 RCT							
Watanabi 2018	17	394	11	400	12.8%	1.57 [0.74, 3.31]	+
Yndigegn 2024	36	2508	46	2512	15.3%	0.78 [0.51, 1.21]	
Subtotal (95% CI)		2902		2912	28.1 %	1.03 [0.53, 2.02]	•
Total events	53		57				
Heterogeneity: Tau ² =	0.14; Chi ^a	² = 2.49, (df = 1 (P =	= 0.11); I	²=60%		
Test for overall effect:	Z = 0.10 (F	^o = 0.92)					
Total (95% CI)		54197		25843	100.0 %	0.69 [0.40, 1.17]	◆
Total events	1424		616				
Heterogeneity: Tau ² =	0.44; Chi ^a	² = 95.40,	df = 7 (P	< 0.000	01); I ^z = 9	3%	
Test for overall effect:	Z = 1.39 (F	^o = 0.17)					Eavours beta blockers, Eavours control
Test for subgroup diff	erences: C	2hi² = 1.5	i2, df = 1	(P = 0.22	2), I ² = 34.1	3%	

Supplemental Figure 5: Forest Plot of Stroke

Supplemental Figure 6: Forest Plot of Heart Failure

	Beta Blo	ckers	Cont	rol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
1.1.1 Cohort							
Al-Bawardy 2024	37	477	46	477	11.3%	0.80 [0.53, 1.22]	
Ishak 2023	462	34253	145	9365	56.7%	0.87 [0.72, 1.05]	-8+
Joo 2021	102	3240	70	1775	21.8%	0.80 (0.59, 1.08)	
Wen 2022	9	415	4	420	1.4%	2.28 [0.71, 7.34]	
Yndigegn 2024 Subtotal (95% CI)	20	2508 40893	22	2512 14549	5.3% 96.6%	0.91 [0.50, 1.66]	
Total events	630	40033	287	14545	30.070	0.00 [0.73, 0.33]	•
Heterogeneity: Tau² =	0.00; Chi ^a	ⁱ = 3.05, (df = 4 (P =	: 0.55); l	²=0%		
Test for overall effect:	Z = 2.08 (F	° = 0.04)					
1.1.2 RCT							
Amano 2023	5	394	10	400	1.7%	0.51 [0.18, 1.47]	
Watanabi 2018	5	394	10	400	1.7%	0.51 [0.18, 1.47]	
Subtotal (95% CI)		788		800	3.4%	0.51 [0.24, 1.08]	
Total events	10		20				
Heterogeneity: Tau² =	0.00; Chi ^a	² = 0.00, (df = 1 (P =	: 1.00); f	²=0%		
Test for overall effect:	Z = 1.77 (F	P = 0.08)					
Total (95% CI)		41681		15349	100.0%	0.84 [0.73, 0.97]	•
Total events	640	11001	307	10010	1001070	0.01[0.10, 0.01]	•
Heteroneneity: Tau²-	0.00 0.00	- 1 99 /	- 007 - 16 - 16	0.66) 1	≅– ∩%		
Tact for overall effect:	7 - 2 37 /	- 4.00, 1 2 - 0.02\	ar – 0 (r [.] –	0.00), 1	- 0 %		0.1 0.2 0.5 i ż ś 10
Test for subaroun diff	2-2.37 (r erences: (- 0.02) 2hi² = 1.9	2 df=1/	ዎ = በ 19	8) P= 45	1%	Favours beta blockers Favours control

It is made available under a CC-BY-NC-ND 4.0 International license .

	Beta Blo	ckers	Cont	rol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
1.3.1 Cohort							
Al-Bawardy 2024	42	477	33	477	2.6%	1.27 [0.82, 1.97]	
Ishak 2023	1415	34253	372	9365	28.3%	1.04 [0.93, 1.16]	-
Joo 2021	141	3240	78	1775	6.5%	0.99 [0.76, 1.30]	_
Won 2020	1367	10624	1469	10624	49.7%	0.93 [0.87, 1.00]	—
Yang 2014	141	2650	85	1325	7.0%	0.83 [0.64, 1.08]	
Subtotal (95% CI)		51244		23566	94.1%	0.97 [0.89, 1.05]	•
Total events	3106		2037				
Heterogeneity: Tau ² =	0.00; Chi ^a	²= 5.61, i	df = 4 (P =	= 0.23); I	² = 29%		
Test for overall effect:	Z = 0.74 (I	P = 0.46)					
1.3.2 RCT							
Watanabi 2018	78	394	75	400	5.9%	1.06 [0.79, 1.40]	
Subtotal (95% CI)		394		400	5.9%	1.06 [0.79, 1.40]	-
Total events	78		75				
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z = 0.37 (I	P = 0.71)					
Total (95% Cl)		51638		23966	100.0%	0.97 [0.90, 1.04]	•
Total events	3184		2112				
Heterogeneity: Tau ² =	0.00; Chi ^a	²= 6.04,	df = 5 (P =	= 0.30); I	²=17%		
Test for overall effect:	Z = 0.79 (I	P = 0.43)					Favours Beta Blockers Favours Control
Test for subaroup diff	erences: (Chi² = 0.3	32. df = 1	(P = 0.5)	7), I ^z = 0%		

Supplemental Figure 7: Forest Plot of Revascularization

It is made available under a CC-BY-NC-ND 4.0 International license .

Study	Selec	tion			Comparal	oility	Outcor	me		Total
	S1	S2	S 3	S4	C		01	02	03	
Al-Bawardy 2016	*	*	*	0	*	*	*	*	0	7*
Chen 2021	*	*	*	*	*	0	*	*	0	7*
Choo 2013	*	*	*	*	*	*	*	*	*	9*
lshak 2023	*	*	*	*	*	*	*	*	*	9*
Joo 2021	*	*	*	*	*	*	0	*	*	8*
Konishi 2015	*	*	*	*	*	*	*	*	*	9*
Lee 2020	*	*	*	*	*	*	*	*	0	8*
Nakatani 2013	*	*	*	*	*	*	*	*	0	8*
Puymirat 2016	*	*	0	*	*	*	*	*	*	8*
Wen 2022	*	*	*	*	*	*	0	*	0	7*
Won 2019	*	*	*	*	*	*	*	*	*	9*
Yang 2014	*	*	*	*	*	*	*	0	*	8*

Supplementary Table 1: Risk of Bias in Observational Studies